Head-to-head evidence
Insulin Lispro vs SHR-3167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Lispro · Humalog
Marketed by Eli Lilly
NCT00551356 · Phase 3 · completed
The study was randomized and compared two active treatments, but it was open-label, enrolled 53 participants, and used a glucose-excursion measure rather than a hard clinical endpoint. Because the registry provides no results, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT06251635 (registry estimate)
SHR-3167
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06688123 · Phase 2 · completed
The study used randomization and an active insulin glargine comparator in 275 participants, but it was open-label rather than blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and no results are currently available to show whether the primary comparison was met.
Next expected readout: December 2026 · NCT07472725 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Lispro's landscape · SHR-3167's landscape